Moomoo AI 已提取核心訊息
On February 13, 2024, Allarity Therapeutics, Inc. (Allarity Therapeutics), a biotechnology firm, announced the completion of a significant financial transaction with 3i, LP. The event, known as the Second Closing, involved the issuance of a senior convertible promissory note valued at $440,000, which is due on February 13, 2025. The note was sold at a 10% discount for $400,000 and is intended to be used for accounts payable and working capital purposes. The agreement allows the note to be converted into common stock at $0.405 per share, subject to certain ownership limitations. Additionally, Allarity Therapeutics has amended the conversion price of its Series A Convertible Preferred Stock to the same price of $0.405. The company has also filed the Sixth Certificate of Amendment to reflect this change. The sale of the securities was made to an accredited investor and was exempt from registration under the Securities Act of 1933, based on exemptions applicable to transactions not involving a public offering.
On February 13, 2024, Allarity Therapeutics, Inc. (Allarity Therapeutics), a biotechnology firm, announced the completion of a significant financial transaction with 3i, LP. The event, known as the Second Closing, involved the issuance of a senior convertible promissory note valued at $440,000, which is due on February 13, 2025. The note was sold at a 10% discount for $400,000 and is intended to be used for accounts payable and working capital purposes. The agreement allows the note to be converted into common stock at $0.405 per share, subject to certain ownership limitations. Additionally, Allarity Therapeutics has amended the conversion price of its Series A Convertible Preferred Stock to the same price of $0.405. The company has also filed the Sixth Certificate of Amendment to reflect this change. The sale of the securities was made to an accredited investor and was exempt from registration under the Securities Act of 1933, based on exemptions applicable to transactions not involving a public offering.
2024年2月13日，生物技術公司Allarity Therapeutics, Inc.（Allarity Therapeutics）宣佈完成與3i, LP的重大財務交易。該活動被稱爲第二次收盤，涉及發行價值44萬美元的優先可轉換期票，該期票將於2025年2月13日到期。該票據以10％的折扣出售，價格爲40萬美元，旨在用於應付賬款和營運資金用途。該協議允許以每股0.405美元的價格將票據轉換爲普通股，但須遵守某些所有權限制。此外，Allarity Therapeutics已將其A系列可轉換優先股的轉換價格修改爲0.405美元的相同價格。該公司還提交了第六份修正證書，以反映這一變化。證券的出售是向合格投資者進行的，根據1933年《證券法》，根據適用於不涉及公開發行交易的豁免，無需註冊。
2024年2月13日，生物技術公司Allarity Therapeutics, Inc.（Allarity Therapeutics）宣佈完成與3i, LP的重大財務交易。該活動被稱爲第二次收盤，涉及發行價值44萬美元的優先可轉換期票，該期票將於2025年2月13日到期。該票據以10％的折扣出售，價格爲40萬美元，旨在用於應付賬款和營運資金用途。該協議允許以每股0.405美元的價格將票據轉換爲普通股，但須遵守某些所有權限制。此外，Allarity Therapeutics已將其A系列可轉換優先股的轉換價格修改爲0.405美元的相同價格。該公司還提交了第六份修正證書，以反映這一變化。證券的出售是向合格投資者進行的，根據1933年《證券法》，根據適用於不涉及公開發行交易的豁免，無需註冊。
有用
沒用